Heart failure hope for kids: diabetes drug tested as new therapy

NCT ID NCT07692256

Recruiting now Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This trial investigates whether empagliflozin, a drug originally used for diabetes, can help children with heart failure. About 60 children aged 1 month to 18 years with confirmed heart failure will receive either standard care plus empagliflozin or standard care alone for 90 days. Researchers will measure changes in heart function and blood markers of heart strain to see if the drug offers additional benefits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin
What this could lead to: If it works, this could point toward a new treatment option for children with heart failure, potentially improving heart function and reducing symptoms.
What could go wrong: This is a small, early-phase study with only 60 children, so results may not apply to all pediatric heart failure patients. Empagliflozin can cause side effects like dehydration or urinary tract infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dilated cardiomyopathy heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ain Shams Hospital
RECRUITING

Cairo, Cairo Governorate, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.